The Motley Fool

Why the Clinuvel Pharmaceuticals share price is down 8% today

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has fallen more than 9% during trading today. CUV shares opened at $35.57 this morning but at the time of writing, the price has dropped to $32.99, a fall of around 8.49%.

The reasons for this drop are not entirely clear, although it may involve some profit taking. At today’s open price, Clinuvel shares were up 97.6% YTD, and 62% over the last three months. These price gains were likely assisted by the company’s inclusion in the S&P/ASX 200 (INDEXASX: XJO) index as of 24 June.

Today’s drop may also involve a delayed reaction to Clinuvel’s ‘communiqué’, which was released to the market yesterday before opening. Clinuvel provided an update on the pending US Food and Drug Administration review of its SCENESSE (afamelanotide) product, which has been extended by three months to 6 October 2019.

Clinuvel hopes that SCENESSE (if approved) will be useful in treating erythropoietic protoporphyria (EPP), of which (according to Clinuvel) there is little effective treatment currently available to US patients, many of whom travel to Europe for treatment.

In its release, the company stated: “although the extension… for three months is not our favoured outcome, we remind all stakeholders that if insurmountable outstanding scientific issues were identified during the filing stage, and/or major deficiencies were identified during their due diligence to date, the FDA has always been able to issue a Refusal to File (RTF) and/ or recommend a withdrawal of the NDA. Since these events had not occurred, we embrace a cautious optimism and bear the patience to a long-awaited outcome.”

For a stock getting ready to rocket in the other direction, don't miss this unique ASX-listed company set to profit off the coming marijuana boom.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!